PDE4A and asthma: Oral PDE4 inhibitors improve lung function, asthma control, and asthma exacerbations with the expense of increased adverse events. Oral PDE4 inhibitors including roflumilast 500 μg may be an alternative treatment to regular bronchodilators and inhaled controllers in patients with mild asthma